The global solid tumor cancer treatment market is anticipated to grow at a CAGR of 12.5% during the forecast period. Product innovations have emerged as a key trend gaining popularity in the solid tumor cancer treatment market. Major companies operating in the market are focusing on innovating new products and treatments to sustain their position in the market. For instance, in March 2022, Shanghai Henlius Biotech, a China-based biopharmaceutical company, launched the PD-1 inhibitor HANSIZHUANG, its first innovative monoclonal antibody. It was developed for the treatment of adults with advanced unresectable or metastatic MSI-H (microsatellite instability-high) solid tumors that have not responded to prior conventional treatments. The approval of HANSIZHUANG gives patients with MSI-H solid tumors fresh hope and better matches the demand for clinical treatment and tumor medicine. It also fosters the high-quality development of China’s biopharmaceutical industry and empowers domestic precision immunotherapy for cancer.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/solid-tumor-cancer-treatment-market
The growing drug approvals for solid tumor cancer treatment will further boost market growth. For instance, in December 2022, SQZ Biotechnology Company announced that the U.S. Food and Drug Administration has granted Fast Track Designation for its Enhanced Antigen Presenting Cells (eAPC) therapeutic candidate for the treatment of solid metastatic tumors. In November 2022, a leading clinical-stage biotechnology company announced that the U.S. Food and Drug Administration had approved the company’s investigational drug application. The study will evaluate VISTA-blocking immunotherapy as a potential treatment for patients with advanced solid tumors. In September 2022, Eli Lilly and Company received the U.S. Food and Drug Administration approval for Retevmo (selpercatinib capsules) for adult patients with locally advanced or metastatic solid tumors.
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
- Segment Covered-
o Type
o Drug Type
o Therapy
o End-User
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- including Amgen Inc., AstraZeneca, Eli Lilly, and Co., F. Hoffman-La Roche Ltd, and others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Solid Tumor Cancer Treatment Market Report Segment
By Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Cervical Cancer
By Drug Type
- Carboplatin
- Cisplatin
- Gemcitabine
- Paclitaxel
- Doxorubicin
- Bevacizumab
- Erlotinib
- Sunitinib
- Everolimusa
By Therapy
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Hormone Therapy
- Surgical Procedures
By End-User
- Hospitals
- Specialty Clinics
- Research Institutes
- Homecare
A full report of Solid Tumor Cancer Treatment Market available @ https://www.omrglobal.com/press-release/global-solid-tumor-cancer-treatment-market
Solid Tumor Cancer Treatment Market Report Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Allergan
- Braun Melsungen AG
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb & Company
- Celgene Corp
- Celldex Therapeutics Inc.
- Reddy’s Laboratories Ltd.
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- Hikma Pharmaceuticals PLC
- Lupin
- Merck & Co. Inc.
- Novartis AG
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
